The DOI matches its Crossref record; 774 of the 774 references it cites were found in a registry or an index.
Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance
Abstract
A number of therapeutic drugs with different structures and mechanisms of action have been reported to undergo metabolic activation by Phase I or Phase II drug-metabolizing enzymes. The bioactivation gives rise to reactive metabolites/intermediates, which readily confer covalent binding to various target proteins by nucleophilic substitution and/or Schiff's base mechanism. These drugs include analgesics (e.g., acetaminophen), antibacterial agents (e.g., sulfonamides and macrolide antibiotics), anticancer drugs (e.g., irinotecan), antiepileptic drugs (e.g., carbamazepine), anti-HIV agents (e.g., ritonavir), antipsychotics (e.g., clozapine), cardiovascular drugs (e.g., procainamide and hydralazine), immunosupressants (e.g., cyclosporine A), inhalational anesthetics (e.g., halothane), nonsteroidal anti-inflammatory drugs (NSAIDSs) (e.g., diclofenac), and steroids and their receptor modulators (e.g., estrogens and tamoxifen). Some herbal and dietary constituents are also bioactivated to reactive metabolites capable of binding covalently and inactivating cytochrome P450s (CYPs). A number of important target proteins of drugs have been identified by mass spectrometric techniques and proteomic approaches. The covalent binding and formation of drug-protein adducts are generally considered to be related to drug toxicity, and selective protein covalent binding by drug metabolites may lead to selective organ toxicity. However, the mechanisms involved in the protein adduct-induced toxicity are largely undefined, although it has been suggested that drug-protein adducts may cause toxicity either through impairing physiological functions of the modified proteins or through immune-mediated mechanisms. In addition, mechanism-based inhibition of CYPs may result in toxic drug-drug interactions. The clinical consequences of drug bioactivation and covalent binding to proteins are unpredictable, depending on many factors that are associated with the administered drugs and patients. Further studies using proteomic and genomic approaches with high throughput capacity are needed to identify the protein targets of reactive drug metabolites, and to elucidate the structure-activity relationships of drug's covalent binding to proteins and their clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
J Heart Lung Transplant 2021;40(4).
(2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.002 · Cited by 6,665
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Cancer chemopreventive activity of resveratrol, a natural product derived from grapes
Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W. W., Fong, H. H. S., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., et al. (1997) · Science · doi:10.1126/science.275.5297.218 · Cited by 4,935 · cited 1×
“The irreversible inhibition of CYPs by resveratrol may be related to its antioxidant and antimutagenic properties (Jang et al., 1997); and inactivation of CYPs bioactivating procarcinogens by herbal constituents would contribute to their chemopreventive action.”
BackgroundThalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059
Metabonomics: a platform for studying drug toxicity and gene function
Nicholson, J. K., Connelly, J., Lindon, J. C., & Holmes, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd728 · Cited by 1,914
Hamer, D. H. (1986) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.55.070186.004405 · Cited by 1,800
Common and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity
Guengerich, F. P. (2001) · Chemical Research in Toxicology · doi:10.1021/tx0002583 · Cited by 1,655
Severe Adverse Cutaneous Reactions to Drugs
Roujeau, J. C., & Stern, R. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311906 · Cited by 1,571
Photochemotherapy of Psoriasis with Oral Methoxsalen and Longwave Ultraviolet Light
Parrish, J. A., Fitzpatrick, T. B., Tanenbaum, L., & Pathak, M. A. (1974) · New England Journal of Medicine · doi:10.1056/nejm197412052912301 · Cited by 1,376 · cited 1×
“8-Methoxypsoralen is a natural furanocoumarin present in many foodstuffs such as parsnips and parsley, which is used in combination with long wavelength ultraviolet light to treat psoriasis, vitiligo, and T cell lymphoma (Anderson and Voorhees, 1980; Edelson et al., 1987; Parrish et al., 1974).”
Background
Cited by
Bruderer, R., Bernhardt, O. M., Gandhi, T., Miladinović, S. M., Cheng, L.-Y., Messner, S., Ehrenberger, T., Zanotelli, V., Butscheid, Y., Escher, C., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.044305 · Cited by 1,238
Tiwari, B., Sellamuthu, B., Ouarda, Y., Drogui, P., Tyagi, R. D., & Buelna, G. (2017) · Bioresource Technology · doi:10.1016/j.biortech.2016.11.042 · Cited by 817
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
Apparent activity in high-throughput screening: origins of compound-dependent assay interference
Thorne, N., Auld, D. S., & Inglese, J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.020 · Cited by 430
Strategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors
Johnson, D. S., Weerapana, E., & Cravatt, B. F. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.21 · Cited by 387
van de Steeg, E., Stránecký, V., Hartmannová, H., Nosková, L., Hřebíček, M., Wagenaar, E., van Esch, A., de Waart, D. R., Oude Elferink, R. P. J., Kenworthy, K. E., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59526 · Cited by 384
Molecular mechanisms underlying chemical liver injury
Gu, X., & Manautou, J. E. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002110 · Cited by 381
Zhou, S.-F., Xue, C. C., Yu, X.-Q., Li, C., & Wang, G. (2007) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31815c16f5 · Cited by 375
Self-citationPharmaceutical metabolites in the environment: Analytical challenges and ecological risks
Celiz, M. D., Tso, J., & Aga, D. S. (2010) · Environmental Toxicology and Chemistry · doi:10.1897/09-173.1 · Cited by 339
Kehrer, J. P., & Klotz, L.-O. (2015) · Critical Reviews in Toxicology · doi:10.3109/10408444.2015.1074159 · Cited by 339
The Nrf2–Keap1 defence pathway: Role in protection against drug-induced toxicity
Copple, I. M., Goldring, C. E., Kitteringham, N. R., & Park, B. K. (2008) · Toxicology · doi:10.1016/j.tox.2007.10.029 · Cited by 329
Herbal bioactivation: The good, the bad and the ugly
Zhou, S., Koh, H.-L., Gao, Y., Gong, Z.-Y., & Lee, E. J. D. (2004) · Life Sciences · doi:10.1016/j.lfs.2003.09.035 · Cited by 256
Self-citationTheory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls
Kumalo, H., Bhakat, S., & Soliman, M. (2015) · Molecules · doi:10.3390/molecules20021984 · Cited by 158
Han, E. J., & Lee, D. S. (2017) · Science of The Total Environment · doi:10.1016/j.scitotenv.2017.03.044 · Cited by 57
Bioactivation of Trimethoprim to Protein-Reactive Metabolites in Human Liver Microsomes
Goldman, J. L., Koen, Y. M., Rogers, S. A., Li, K., Leeder, J. S., & Hanzlik, R. P. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.072041 · Cited by 20
Metadata
- Authors
- Zhou, S., Chan, E., Duan, W., Huang, M., & Chen, Y.-Z.
- Venue
- Drug Metabolism Reviews
- Publisher
- Informa UK Limited
- Published
- 2005-01
- Volume
- 37
- Issue
- 1
- Pages
- 41-213
- ISSN
- 0360-2532 (ISSN-L)
- 1097-9883
- OpenAlex
- W1997486990
- Cited by
- 274
- References
- 774
- FWCI
- 13.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.